ESMO 2024: Targeting the Treatment Challenges of Small Cell Lung Cancer - Episode 7
Panelists discuss how the risks and clinical benefits of tarlatamab in relapsed or refractory extensive-stage small cell lung cancer must be carefully evaluated, considering the implications of bBlack bBox warnings for cytokine release syndrome and immune effector cell–-associated neurotoxicity syndrome, as well as the challenges of managing outpatient therapy for patients distant from treatment facilities, while also exploring the potential for reduced monitoring time between infusions given the safety profile observed in clinical studies.
Video content above is prompted by the following:
7. [All Faculty:] How do you weigh the risks vs clinical benefits of treatment with tarlatamab in relapsed or refractory extensive-stage small cell lung cancer (ES-SCLC)?